APA (7th ed.) Citation

NM, B., J, A., M, B., MS, B., GE, F., ES, G., . . . HA, S. (2002). Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: Additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Archives of ophthalmology (Chicago, Ill. : 1960), 120(11), 1443. https://doi.org/10.1001/archopht.120.11.1443

Chicago Style (17th ed.) Citation

NM, Bressler, et al. "Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients with Age-related Macular Degeneration: Additional Information Regarding Baseline Lesion Composition's Impact on Vision Outcomes-TAP Report No. 3." Archives of Ophthalmology (Chicago, Ill. : 1960) 120, no. 11 (2002): 1443. https://doi.org/10.1001/archopht.120.11.1443.

MLA (9th ed.) Citation

NM, Bressler, et al. "Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients with Age-related Macular Degeneration: Additional Information Regarding Baseline Lesion Composition's Impact on Vision Outcomes-TAP Report No. 3." Archives of Ophthalmology (Chicago, Ill. : 1960), vol. 120, no. 11, 2002, p. 1443, https://doi.org/10.1001/archopht.120.11.1443.